We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$415M
AUM Growth
+$35.8M
Cap. Flow
+$32.9M
Cap. Flow %
7.93%
Top 10 Hldgs %
52.35%
Holding
76
New
10
Increased
22
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$15.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.1M
3
ILMN icon
Illumina
ILMN
+$12.8M
4
INCY icon
Incyte
INCY
+$10.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.79M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
UTHR icon
United Therapeutics
UTHR
+$7.77M
4
XLRN
Acceleron Pharma
XLRN
+$7.59M
5
BIIB icon
Biogen
BIIB
+$7.54M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
26
Regeneron Pharmaceuticals
REGN
$83.2B
$4.66M 1.12%
7,700
-29,500
-79% -$18.3M
GH icon
27
Guardant Health
GH
$22.6B
$4.56M 1.1%
36,500
+19,500
+115% +$2.32M
BMRN icon
28
BioMarin Pharmaceuticals
BMRN
$12.6B
$4.26M 1.03%
55,156
– –
ZLAB icon
29
Zai Lab
ZLAB
$3.01B
$4.1M 0.99%
38,958
+26,158
+204% +$3.76M
DYN icon
30
Dyne Therapeutics
DYN
$4.87B
$4.06M 0.98%
250,000
+115,000
+85% +$2.04M
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.99M 0.72%
235,000
+64,179
+38% +$845K
ITCI
32
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.96M 0.71%
79,456
– –
IDYA icon
33
IDEAYA Biosciences
IDYA
$4.03B
$2.78M 0.67%
+109,000
New +$2.55M
AUPH icon
34
Aurinia Pharmaceuticals
AUPH
$2.19B
$2.72M 0.66%
123,500
-175,000
-59% -$2.78M
STRO icon
35
Sutro Biopharma
STRO
$353M
$2.63M 0.63%
13,933
– –
LEGN icon
36
Legend Biotech
LEGN
$3.99B
$2.5M 0.6%
+49,500
New +$2.06M
HCM icon
37
HUTCHMED
HCM
$2.16B
$2.48M 0.6%
68,000
– –
ENTA icon
38
Enanta Pharmaceuticals
ENTA
$402M
$2.26M 0.55%
40,000
+5,953
+17% +$294K
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
$2.05M 0.49%
+135,000
New +$2.11M
BPMC
40
DELISTED
Blueprint Medicines
BPMC
$2M 0.48%
19,500
– –
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$397M
$1.88M 0.45%
+63,000
New +$2.29M
HARP
42
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.7M 0.41%
+21,500
New +$2.16M
ALLK
43
DELISTED
Allakos
ALLK
$1.66M 0.4%
15,700
– –
FATE icon
44
Fate Therapeutics
FATE
$304M
$1.66M 0.4%
+28,000
New +$2.2M
SWTX
45
DELISTED
SpringWorks Therapeutics
SWTX
$1.58M 0.38%
+25,000
New +$1.93M
NKTX icon
46
Nkarta
NKTX
$197M
$1.57M 0.38%
56,445
-13,555
-19% -$429K
KOD icon
47
Kodiak Sciences
KOD
$2.46B
$1.55M 0.37%
+16,200
New +$1.5M
IONS icon
48
Ionis Pharmaceuticals
IONS
$10.4B
$1.5M 0.36%
44,781
-137,000
-75% -$5.16M
IOVA icon
49
Iovance Biotherapeutics
IOVA
$3.74B
$1.43M 0.34%
58,000
– –
NBP
50
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$1.3M 0.31%
18,000
+12,000
+200% +$868K
1
2
3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2021 Portfolio in Review

As of Q3 2021, International Biotechnology Trust held 76 positions worth $415M, up 9.5% from $379M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust deployed $32.9M of net new capital in Q3 2021, opening 10 new positions and adding to 22 existing holdings. Its largest new stake was Illumina: 27,756 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $18.3M trimmed.

  • International Biotechnology Trust's largest Q3 2021 buy was Illumina: 27,756 shares worth $10.9M.
  • International Biotechnology Trust added most to Amgen in Q3 2021, an estimated $15.5M increase.
  • International Biotechnology Trust's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $18.3M.
  • International Biotechnology Trust fully exited United Therapeutics in Q3 2021, selling an estimated $7.77M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $415M portfolio in Q3 2021.
  • International Biotechnology Trust opened 10 new positions and closed 8 in Q3 2021.
  • International Biotechnology Trust's portfolio value rose 9.5% quarter-over-quarter to $415M.

Based on International Biotechnology Trust's 13F filing for Q3 2021, filed 12 Nov 2021.